Prior Authorization for GLP-1 Medications: Why Requests Get Denied and What Patients Can Do

Prior authorization exists, in theory, to ensure that expensive medications are prescribed appropriately. In practice, it functions as a rationing mechanism that places a significant administrative burden on prescribing physicians and creates delays that deter many patients from pursuing treatment at all. For GLP-1 medications specifically, the prior authorization process has become one of the primary access barriers between patients and clinically indicated treatment.

What follows is a clinician-level explanation of how this process actually works—what criteria are evaluated, why denials happen, and what the evidence suggests about navigating it effectively.

What Prior Authorization Actually Reviews

When a physician submits a prior authorization request for a GLP-1 medication, the insurer’s clinical review team evaluates several distinct criteria. These are not standardized across plans, but the following elements appear consistently:

BMI documentation

Most plans require a documented BMI of 30 kg/m² or higher, or a BMI of 27 or higher in the presence of at least one qualifying weight-related comorbidity. The BMI must typically be recorded in the medical chart within a defined recent window—often 12 months. BMI calculated from patient-reported height and weight, rather than clinician-measured values, is frequently rejected.

Comorbidity documentation

For patients with BMI between 27 and 29.9, the comorbidity requirement is critical. Qualifying conditions typically include hypertension, type 2 diabetes or prediabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. The comorbidity must be documented in the clinical record with an ICD-10 code—a verbal mention in a progress note without a formal diagnosis code is routinely grounds for denial.

Prior treatment documentation

The most commonly cited reason for PA denial in obesity-indication GLP-1 requests is insufficient documentation of prior weight-loss attempts. Most plans require evidence of at least 3–6 months of structured lifestyle intervention—behavioral counseling, supervised diet program, or documented clinical nutrition referral—with failure to achieve or maintain adequate weight loss. Patients who have attempted weight loss independently, without documented clinical involvement, typically cannot use those attempts to satisfy this criterion.

Step therapy requirements

Step therapy—also called fail-first protocols—requires patients to try and fail on older, less effective medications before a GLP-1 will be authorized. For weight management, step therapy requirements vary: some plans require documented trial of orlistat or phentermine-topiramate; others are more flexible. Step therapy requirements are more common for GLP-1s than for most other medication classes due to cost.

Why Denials Happen Even With Appropriate Clinical Criteria

A significant portion of prior authorization denials are not clinically justified—they result from administrative deficiencies rather than the patient genuinely failing to meet coverage criteria. Understanding the specific categories of avoidable denial is useful:

Incomplete submission

PA submissions require specific forms, specific supporting documentation, and—increasingly—electronic submission through specific portals. Submissions that use incorrect forms, omit required fields, or include documentation as unsupported file formats are frequently rejected on procedural grounds rather than reviewed on clinical merit.

Coding errors

The ICD-10 codes submitted with the PA request must match the coverage criteria for the requested drug. Submitting E66.01 (morbid obesity due to excess calories) when the plan requires E66.09, or failing to include a comorbidity code that qualifies the patient for a lower BMI threshold, commonly results in denial.

Prescriber not recognized

Some plans restrict GLP-1 prescribing for weight management to specialists in endocrinology or obesity medicine. A PA submitted by a primary care physician, nurse practitioner, or telemedicine provider may be denied on prescriber eligibility grounds, even when the clinical criteria are fully met.

The Appeals Process: What the Evidence Shows

An initial denial should not be treated as a final determination. Multiple analyses of insurance appeal data have found that first-level internal appeals for GLP-1 medications are overturned at rates of approximately 35–45%, provided the appeal is submitted with adequate supporting documentation. This is a meaningful reversal rate that suggests initial denials frequently reflect missing information rather than genuine ineligibility.

Internal appeals

The first level of appeal is an internal review conducted by the insurer. This must typically be filed within 30–60 days of the denial notice, depending on plan terms. The appeal should include: a detailed letter of medical necessity from the prescribing physician referencing specific clinical guidelines (AHA/ACC, AACE, TOS), all documentation that was requested but may not have been included in the original submission, and any additional clinical evidence supporting the treatment decision.

A physician-authored letter of medical necessity that specifically cites peer-reviewed trial data (STEP trials, SURMOUNT trials) and calculates the cardiovascular risk reduction expected with treatment is substantially more persuasive than a generic request. Insurers are required to have a licensed clinical professional review appeals, and direct engagement with that clinical logic is more effective than procedural arguments.

External appeals

If the internal appeal is denied, patients in most states have the right to request an external independent review. External reviews are conducted by clinical reviewers who are independent of the insurer, and internal denial rates cannot be used to bias the outcome. External appeals for GLP-1 medications are overturned at somewhat lower rates than internal appeals, but remain a legitimate recourse.

Expedited appeals

When a delay in treatment poses a significant risk to the patient’s health, an expedited review can be requested. Expedited timelines are 72 hours for urgent cases versus 30 days for standard appeals. The clinical basis for urgency must be documented—metabolic risk, cardiovascular risk, or significant functional impairment from obesity-related conditions are the strongest grounds.

What Patients Can Do Proactively

The prior authorization process is substantially easier to navigate before a denial than after one. Patients who are aware that they will need PA for a GLP-1 medication can take several steps that meaningfully reduce denial risk:

• Ask the prescribing physician’s office to verify coverage criteria with the specific insurer before submitting the PA request—each plan has its own criteria, and these are obtainable in advance
• Ensure that all relevant diagnoses are coded correctly in the medical record before the PA is submitted, not added retrospectively after a denial
• Request documentation from any clinician who has supervised prior weight-loss efforts, even informally—a letter from a dietitian, a behavioral counseling referral record, or documented advice from a primary care provider all count
• Ask the prescribing physician whether the practice has a dedicated PA coordinator, and if not, whether external PA assistance services are available—many obesity medicine practices now use third-party services specifically for this

When the Insurance Path Is Not Viable

For patients who have exhausted the appeals process without success, or who calculate that the expected timeline and outcome of pursuing coverage does not justify the delay, physician-supervised telehealth programs that operate on a cash-pay basis provide an alternative pathway. These programs typically price GLP-1 access at $149–$398 per month depending on medication type and program structure, without prior authorization requirements.

The tradeoff involves both clinical and financial considerations: compounded medications available through these programs differ from FDA-approved brand-name formulations in ways that a prescribing physician should explain, and the monthly cost, while lower than retail brand-name pricing, is not equivalent to a covered prescription.